
Weight loss jabs could improve the symptoms of heart failure in obese patients, a new study has found.
US researchers explored the use of semaglutide – which is sold under the brand names Ozempic, Wegovy and Rybelsus – to treat overweight people with a condition called heart failure with preserved ejection fraction (HFpEF).